Search research articles
Contact Us
Filters
Showing results (31-40 of 51) with videos related to
Page
of 6
Sort By:
Frontiers in Immunology
|
February 9, 2018
NLRC4 Inflammasome-Driven Immunogenicity of a Recombinant MVA Mucosal Vaccine Encoding Flagellin
Stephanie L Sanos, Ronny Kassub, Marco Testori, et al.
Vaccine
|
November 27, 2007
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge
Sharon E Frey, Frances K Newman, Jeffrey S Kennedy, et al.
Nature Communications
|
November 8, 2019
Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
José Medina-Echeverz, Maria Hinterberger, Marco Testori, et al.
Journal of Virology
|
March 24, 2017
Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles
Marc Schweneker, Andrea S Laimbacher, Gert Zimmer, et al.
Plos One
|
April 14, 2018
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial
Edgar Turner Overton, Steven J Lawrence, Eva Wagner, et al.
The New England Journal of Medicine
|
November 14, 2019
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
Phillip R Pittman, Matthew Hahn, HeeChoon S Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma
Massimo Di Nicola, Carmelo Carlo-Stella, Roberta Mortarini, et al.
The Journal of Infectious Diseases
|
March 6, 2021
Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses
Sharon E Frey, Jack T Stapleton, Zuhair K Ballas, et al.
Scientific Reports
|
March 30, 2023
Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication
Maria Hinterberger, Kathrin Endt, Barbara Bathke, et al.
The Journal of Infectious Diseases
|
July 30, 2020
Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine
Elke Jordan, Steven J Lawrence, Thomas P H Meyer, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 51) with videos related to
Sort By:
Page
of 6
Frontiers in Immunology
|
February 9, 2018
NLRC4 Inflammasome-Driven Immunogenicity of a Recombinant MVA Mucosal Vaccine Encoding Flagellin
Stephanie L Sanos, Ronny Kassub, Marco Testori, et al.
Vaccine
|
November 27, 2007
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge
Sharon E Frey, Frances K Newman, Jeffrey S Kennedy, et al.
Nature Communications
|
November 8, 2019
Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
José Medina-Echeverz, Maria Hinterberger, Marco Testori, et al.
Journal of Virology
|
March 24, 2017
Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles
Marc Schweneker, Andrea S Laimbacher, Gert Zimmer, et al.
Plos One
|
April 14, 2018
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial
Edgar Turner Overton, Steven J Lawrence, Eva Wagner, et al.
The New England Journal of Medicine
|
November 14, 2019
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
Phillip R Pittman, Matthew Hahn, HeeChoon S Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma
Massimo Di Nicola, Carmelo Carlo-Stella, Roberta Mortarini, et al.
The Journal of Infectious Diseases
|
March 6, 2021
Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses
Sharon E Frey, Jack T Stapleton, Zuhair K Ballas, et al.
Scientific Reports
|
March 30, 2023
Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication
Maria Hinterberger, Kathrin Endt, Barbara Bathke, et al.
The Journal of Infectious Diseases
|
July 30, 2020
Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine
Elke Jordan, Steven J Lawrence, Thomas P H Meyer, et al.
Page
of 6